Literature DB >> 30488353

Osteopontin Attenuates Secondary Neurodegeneration in the Thalamus after Experimental Stroke.

Anne Ladwig1, Rebecca Rogall1, Jörg Hucklenbroich1, Antje Willuweit2, Michael Schoeneck2, Karl-Josef Langen2, Gereon R Fink1,3, M Adele Rueger1,3, Michael Schroeter4,5.   

Abstract

Cortical cerebral ischemia elicits neuroinflammation as well as secondary neuronal degeneration in remote areas. Locally distinct and specific secondary neurodegeneration affecting thalamic nuclei connected to cortical areas highlights such processes. Osteopontin (OPN) is a cytokine-like glycoprotein that is excreted in high amounts after cerebral ischemia and exerts various immunomodulatory functions. We here examined putative protective effects of OPN in secondary thalamic degeneration. We subjected male Wistar rats to photothrombosis and subsequently injected OPN or placebo intracerebroventricularly. Immunohistochemical and fluorescence staining was used to detect the extent of neuronal degeneration and microglia activation. Ex vivo autoradiography with radiotracers available for human in vivo PET studies, i.e., CIS-4-[18F]Fluor-D-Proline (D-cis-[18F]FPRO), and [6-3H]thymidine ([3H]thymidine), confirmed degeneration and proliferation, respectively. We found secondary neurodegeneration in the thalamus characterized by microglial activation and neuronal loss. Neuronal loss was restricted to areas of microglial infiltration. Treatment with OPN significantly decreased neurodegeneration, inflammation and microglial proliferation. Microglia displayed morphological signs of activation without expressing markers of M1 or M2 polarization. D-CIS-[18F]FPRO-uptake mirrored attenuated degeneration in OPN-treated animals. Notably, [3H]thymidine and BrdU-staining revealed increased stem cell proliferation after treatment with OPN. The data suggest that OPN is able to ameliorate secondary neurodegeneration in thalamic nuclei. These effects can be visualized by radiotracers D-CIS-[18F]FPRO and [3H]thymidine, opening new vistas for translational studies. Graphical Abstract Intracerebroventricular injection of osteopontin attenuates thalamic degeneration after cortical ischemia (pink area). Disruption of thalamocortical connections (blue) and degeneration of thalamic nuclei (encircled) leads to microglia activation. Osteopontin protects from both neurodegeneration and microglia activation as assessed by histological analysis and autoradiograpic studies.

Entities:  

Keywords:  Microglia, autoradiography; Neuroinflammation; Osteopontin; Secondary neurodegeneration; Stroke

Year:  2018        PMID: 30488353     DOI: 10.1007/s11481-018-9826-1

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  60 in total

1.  Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195.

Authors:  S Pappata; M Levasseur; R N Gunn; R Myers; C Crouzel; A Syrota; T Jones; G W Kreutzberg; R B Banati
Journal:  Neurology       Date:  2000-10-10       Impact factor: 9.910

Review 2.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Increased thalamic neurodegeneration following ischaemic cortical stroke in osteopontin-deficient mice.

Authors:  Michael Schroeter; Philipp Zickler; David T Denhardt; Hans-Peter Hartung; Sebastian Jander
Journal:  Brain       Date:  2006-04-24       Impact factor: 13.501

4.  Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives.

Authors:  Pia Villa; Johan van Beek; Anna Kirstine Larsen; Jens Gerwien; Søren Christensen; Anthony Cerami; Michael Brines; Marcel Leist; Pietro Ghezzi; Lars Torup
Journal:  J Cereb Blood Flow Metab       Date:  2006-07-12       Impact factor: 6.200

5.  Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells.

Authors:  Eun Mi Hur; Sawsan Youssef; M Edward Haws; Susan Y Zhang; Raymond A Sobel; Lawrence Steinman
Journal:  Nat Immunol       Date:  2006-12-03       Impact factor: 25.606

6.  Heterogeneity of the microglial response in photochemically induced focal ischemia of the rat cerebral cortex.

Authors:  M Schroeter; S Jander; O W Witte; G Stoll
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

7.  Neural damage in the rat thalamus after cortical infarcts.

Authors:  H Iizuka; K Sakatani; W Young
Journal:  Stroke       Date:  1990-05       Impact factor: 7.914

8.  Neuroprotection by osteopontin in stroke.

Authors:  Robert Meller; Susan L Stevens; Manabu Minami; Jennifer A Cameron; Sonya King; Holly Rosenzweig; Kristian Doyle; Nikola S Lessov; Roger P Simon; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2005-02       Impact factor: 6.200

9.  Transient upregulation of osteopontin mRNA in hippocampus and striatum following global forebrain ischemia in rats.

Authors:  M Y Lee; S L Shin; Y S Choi; E J Kim; J H Cha; M H Chun; S B Lee; S Y Kim
Journal:  Neurosci Lett       Date:  1999-08-20       Impact factor: 3.046

10.  Inflammatory gene profiling in the developing mouse brain after hypoxia-ischemia.

Authors:  Maj Hedtjärn; Carina Mallard; Henrik Hagberg
Journal:  J Cereb Blood Flow Metab       Date:  2004-12       Impact factor: 6.200

View more
  5 in total

1.  Osteopontin/secreted phosphoprotein-1 behaves as a molecular brake regulating the neuroinflammatory response to chronic viral infection.

Authors:  Farina J Mahmud; Yong Du; Elizabeth Greif; Thomas Boucher; Robert F Dannals; William B Mathews; Martin G Pomper; Polina Sysa-Shah; Kelly A Metcalf Pate; Claire Lyons; Bess Carlson; Maria Chacona; Amanda M Brown
Journal:  J Neuroinflammation       Date:  2020-09-17       Impact factor: 8.322

Review 2.  The Yin-Yang of osteopontin in nervous system diseases: damage versus repair.

Authors:  Giuseppe Cappellano; Domizia Vecchio; Luca Magistrelli; Nausicaa Clemente; Davide Raineri; Camilla Barbero Mazzucca; Eleonora Virgilio; Umberto Dianzani; Annalisa Chiocchetti; Cristoforo Comi
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

Review 3.  Neuroinflammation as a Key Driver of Secondary Neurodegeneration Following Stroke?

Authors:  Shannon M Stuckey; Lin Kooi Ong; Lyndsey E Collins-Praino; Renée J Turner
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

4.  Determining the effect of aging, recovery time, and post-stroke memantine treatment on delayed thalamic gliosis after cortical infarct.

Authors:  Gab Seok Kim; Jessica M Stephenson; Abdullah Al Mamun; Ting Wu; Monica G Goss; Jia-Wei Min; Jun Li; Fudong Liu; Sean P Marrelli
Journal:  Sci Rep       Date:  2021-06-15       Impact factor: 4.379

Review 5.  Neuronal Loss after Stroke Due to Microglial Phagocytosis of Stressed Neurons.

Authors:  Guy C Brown
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.